Brief: Cingulate Inc. Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Clinical And Business Update

Cingulate

10/03/2023 21:43

March 10 (Reuters) - Cingulate Inc  CING.O :
    * . REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL
RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
    * CTX-1301 PIVOTAL PHASE 3 TRIAL IN PEDIATRIC/ADOLESCENT
PATIENTS
PLANNED TO BEGIN MID-2023
    * CTX-1301 PHASE 3 ADULT DOSE-OPTIMIZATION STUDY ONGOING;
RESULTS
EXPECTED 3Q 2023
    * QTRLY LOSS PER SHARE $0.41
    * Q4 EARNINGS PER SHARE VIEW $-0.37 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX9knlVc 
Further company coverage:  CING.O 

 ((Reuters.Briefs@thomsonreuters.com;;))